Increased bone mass through elevated Wnt1‐class signaling via the LRP6 receptor was evident in the current investigation, where elevations in trabecular bone volume were apparent after 7, 14, and 21 days of anti‐LRP6 treatment in naïve mice, as shown previously by Chang and colleagues.(17) Importantly, treatment of 5TGM1‐bearing mice with this novel anti‐LRP6 antibody prevented myeloma‐induced trabecular bone loss in both femurs and L4 lumbar vertebrae, which consequently improved vertebral fracture resistance. Here, WNT1 is linked to plasma cell myeloma.